Incubation:Article Title: Neutrophil extracellular traps drive osteoporosis via NCF2-dependent signaling: integrated transcriptomics with mechanistic validation
Article Snippet: .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257). .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257).
Article Title: mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma.
Article Snippet: Acral melanoma (AM), a rare and aggressive subtype with 5-year survival rates below 16%, exhibits limited response to CDK4/6 inhibitors (CDK4i/6i) despite frequent pathway alterations.. Here, we identify AKT-mTOR signaling as a critical escape mechanism triggered by CDK4/6 inhibition.. Using a genetically diverse panel of AM cell lines, we demonstrate that CDK4i/6i induces rapid hyperactivation of AKT (pS473) and mTORC1 (pS6 S240/244) alongside Rb dephosphorylation.
Article Title: Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells.
Article Snippet: .. Subsequently, cells were incubated in the blocking solution with a 1:500 dilution of the 53BP1 antibody (Cat No. NB 100-0304, Rabbit, Novus Biologicals) for 1 hour at room temperature. .. After three washes of 5 minutes each in 1X PBS, the samples were incubated for 1 hour at room temperature with a 1:500 dilution of Alexa Fluor 555 in the blocking solution (Cat No. A21429, Goat anti-Rabbit, Invitrogen).
Article Title: Induced Mammary Epithelial Cell-Derived Extracellular Vesicles Promote the Repair of Skin Trauma
Article Snippet: .. After fibroblasts were induced for 8 days, the cells were fixed in 4% paraformaldehyde for 20 min at room temperature, a blocking solution (PBS containing 100 mmol/L glycine and 0.3% BSA) was added, and then, 1% Triton X-100 was added and incubated at room temperature for 15 min. Then, a blocking solution (100 mmol/L glycine and 0.3% BSA in PBS buffer) was added for washing, and the samples were blocked with 1% BSA for 1.5 h at room temperature, followed by the addition of a primary antibody (Mouse monoclonal anti-CK14, NOVUS, Littleton, CO, USA, Cat#NBP2-45032, RRID:AB_3309227 and Mouse monoclonal anti-CK18, NOVUS, Littleton, CO, USA, Cat#NBP2-44951, RRID:AB_2811032), incubation at 4 °C in the refrigerator overnight, and then incubation at room temperature in the dark. .. After incubation with secondary antibody for 1.5 h (Alexa Fluor 488 Donkey Anti-mouse, Abcam, Cambridge, MA, USA, Cat#ab150109; RRID: AB_2571721 and Alexa Fluor 555 Donkey Anti-mouse, Abcam, Cambridge, MA, USA, Cat#ab150100; RRID: AB_2890133), images were taken under a fluorescence microscope and recorded.
Blocking Assay:Article Title: Neutrophil extracellular traps drive osteoporosis via NCF2-dependent signaling: integrated transcriptomics with mechanistic validation
Article Snippet: .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257). .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257).
Article Title: mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma.
Article Snippet: Acral melanoma (AM), a rare and aggressive subtype with 5-year survival rates below 16%, exhibits limited response to CDK4/6 inhibitors (CDK4i/6i) despite frequent pathway alterations.. Here, we identify AKT-mTOR signaling as a critical escape mechanism triggered by CDK4/6 inhibition.. Using a genetically diverse panel of AM cell lines, we demonstrate that CDK4i/6i induces rapid hyperactivation of AKT (pS473) and mTORC1 (pS6 S240/244) alongside Rb dephosphorylation.
Article Title: Tumor Cell–Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy
Article Snippet: .. The blocking solution was replaced with goat anti–mouse catalase (Novus Biologicals, AF3398-SP), rat anti–mouse Lamp1 (Thermo Fisher Scientific, cat. #14-1071-82) or mouse anti–mouse Atp5a (Abcam, ab14748) and left to incubate overnight at 4°C. .. The blocking solution was replaced with goat anti–mouse catalase (Novus Biologicals, AF3398-SP), rat anti–mouse Lamp1 (Thermo Fisher Scientific, cat. #14-1071-82) or mouse anti–mouse Atp5a (Abcam, ab14748) and left to incubate overnight at 4°C.
Article Title: Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells.
Article Snippet: .. Subsequently, cells were incubated in the blocking solution with a 1:500 dilution of the 53BP1 antibody (Cat No. NB 100-0304, Rabbit, Novus Biologicals) for 1 hour at room temperature. .. After three washes of 5 minutes each in 1X PBS, the samples were incubated for 1 hour at room temperature with a 1:500 dilution of Alexa Fluor 555 in the blocking solution (Cat No. A21429, Goat anti-Rabbit, Invitrogen).
Article Title: Platelet-Rich Plasma (PRP) Mitigates Silver Nanoparticle (AgNP)-Induced Pulmonary Fibrosis via iNOS/CD68/CASP3/TWIST1 Regulation: An Experimental Study and Bioinformatics Analysis.
Article Snippet: .. The sections were then exposed to blocking solution for 20 min, and an iNOS-recognizing primary antibody (rat monoclonal antibody, 1:500 dilution; Brand: Novus Biologicals, Cat No. NB300-605NCL Transduction Laboratories, San Diego, California, USA) was subsequently added for an additional night at 4 ◦C [73]. .. In accordance with the manufacturer’s instructions, a CD68-recognizing primary antibody (mouse monoclonal antibody, 1:200 dilution; Cat No. ab53444 -L-CD68; Leica Biosystems, Benton La, Newcastle Ltd., UK) was subsequently added to a humidified chamber [74,75].
Article Title: Induced Mammary Epithelial Cell-Derived Extracellular Vesicles Promote the Repair of Skin Trauma
Article Snippet: .. After fibroblasts were induced for 8 days, the cells were fixed in 4% paraformaldehyde for 20 min at room temperature, a blocking solution (PBS containing 100 mmol/L glycine and 0.3% BSA) was added, and then, 1% Triton X-100 was added and incubated at room temperature for 15 min. Then, a blocking solution (100 mmol/L glycine and 0.3% BSA in PBS buffer) was added for washing, and the samples were blocked with 1% BSA for 1.5 h at room temperature, followed by the addition of a primary antibody (Mouse monoclonal anti-CK14, NOVUS, Littleton, CO, USA, Cat#NBP2-45032, RRID:AB_3309227 and Mouse monoclonal anti-CK18, NOVUS, Littleton, CO, USA, Cat#NBP2-44951, RRID:AB_2811032), incubation at 4 °C in the refrigerator overnight, and then incubation at room temperature in the dark. .. After incubation with secondary antibody for 1.5 h (Alexa Fluor 488 Donkey Anti-mouse, Abcam, Cambridge, MA, USA, Cat#ab150109; RRID: AB_2571721 and Alexa Fluor 555 Donkey Anti-mouse, Abcam, Cambridge, MA, USA, Cat#ab150100; RRID: AB_2890133), images were taken under a fluorescence microscope and recorded.
Article Title: In vitro characterization of antimicrobial efficacy and cytotoxicity of polyvinylpyrrolidone-iodine, N-acetylcysteine, methylglyoxal, and N-chlorotaurine as alternative antimicrobials in treating bovine clinical endometritis
Article Snippet: Then, cells were fixated with 300 μL/well of an ice-cold 1:1 mixture of acetone (Sigma–Aldrich, Steinheim, Germany) and methanol (Avantor Performance Materials Poland, Gliwice, Poland) for 5 min. As a next step, cells were blocked at room temperature with 300 μL/well of a blocking solution consisting of 0.25% Triton X-100 (Sigma–Aldrich, Steinheim, Germany) and 1% BSA in PBS. .. After removing the blocking solution, the first antibody, a primary mouse pan-anticytokeratin (C11; Novus Biologicals, Wiesbaden, Germany), was diluted 1:100 in the blocking solution and added to wells 1 and 3 at 150 μL/well. ..
Binding Assay:Article Title: Neutrophil extracellular traps drive osteoporosis via NCF2-dependent signaling: integrated transcriptomics with mechanistic validation
Article Snippet: .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257). .. The sections were incubated in a blocking solution to reduce non-specific binding, followed by overnight incubation at 4°C with primary antibodies: VDAC1 (Novus Biologicals, NBP3-15871), PLCG2 (Novus Biologicals, NBP1-86030), and NCF2 (Novus Biologicals, NBP3-16257).
Transduction:Article Title: Platelet-Rich Plasma (PRP) Mitigates Silver Nanoparticle (AgNP)-Induced Pulmonary Fibrosis via iNOS/CD68/CASP3/TWIST1 Regulation: An Experimental Study and Bioinformatics Analysis.
Article Snippet: .. The sections were then exposed to blocking solution for 20 min, and an iNOS-recognizing primary antibody (rat monoclonal antibody, 1:500 dilution; Brand: Novus Biologicals, Cat No. NB300-605NCL Transduction Laboratories, San Diego, California, USA) was subsequently added for an additional night at 4 ◦C [73]. .. In accordance with the manufacturer’s instructions, a CD68-recognizing primary antibody (mouse monoclonal antibody, 1:200 dilution; Cat No. ab53444 -L-CD68; Leica Biosystems, Benton La, Newcastle Ltd., UK) was subsequently added to a humidified chamber [74,75].
|